FGR Kinase Controls Lysosome Numbers by Shuttling from Cell Surface to Lysosome
A newly identified signaling axis shows how surface signals govern lysosome biogenesis via FGR kinase and TFEB — a key aging mechanism.
Summary
Cells must constantly regulate how many lysosomes they maintain — the cellular recycling organelles critical for clearing damaged proteins and organelles, both hallmarks of aging. Researchers discovered that the enzyme FGR, a tyrosine kinase, travels from the cell surface inward along the endosome pathway and ultimately reaches lysosomes. There, FGR activates AKT2, which phosphorylates the transcription factors TFEB and TFE3, keeping them inactive and suppressing new lysosome production. When FGR is blocked or absent, TFEB and TFE3 become active, dramatically increasing lysosome numbers. This pathway was first found in roundworms and confirmed in mammalian cells, suggesting it is evolutionarily conserved. Because lysosomal decline is a central driver of cellular aging, understanding how lysosome numbers are controlled offers new targets for longevity-oriented interventions.
Detailed Summary
Lysosomes are the cell's primary recycling and waste-disposal system, and their function declines significantly with age. This decline contributes to the accumulation of damaged proteins and organelles — a hallmark of cellular aging linked to neurodegeneration, cardiovascular disease, and metabolic dysfunction. Understanding what controls lysosome biogenesis is therefore directly relevant to healthy aging and longevity research.
This study identifies FGR, a non-receptor tyrosine kinase in the SRC family, as a critical regulator of lysosome numbers in mammalian cells. Using a Caenorhabditis elegans model engineered to screen for activators of TFE3 — a master transcription factor governing lysosomal gene expression — the researchers identified the worm homologs SRC-1 and SRC-2, and confirmed FGR as the mammalian equivalent. Inhibiting or deleting FGR in mammalian cells caused a significant TFEB/TFE3-dependent increase in lysosome abundance.
Mechanistically, FGR begins at the plasma membrane but is internalized through endocytosis, travels along the endosome-lysosome pathway, and ultimately localizes to lysosomes. At the lysosomal membrane, FGR recruits and activates AKT2. Activated AKT2 then phosphorylates TFEB and TFE3, preventing their nuclear translocation and thus suppressing lysosome biogenesis. This creates a feedback loop where the cell's surface sampling of its environment — via endocytosis — feeds into decisions about lysosomal capacity.
For longevity science, this pathway is compelling because TFEB/TFE3 activation is already associated with extended lifespan in model organisms, and because lysosomal decline is a root cause of age-related cellular dysfunction. FGR inhibition emerges as a potential lever to boost autophagy and lysosomal clearance, relevant to diseases including neurodegeneration and metabolic aging.
Caveats include that findings are primarily based on worm and cell culture models, with limited direct evidence in aged mammalian tissues or in vivo. The summary is based on the abstract only, as the full text was not accessible.
Key Findings
- FGR kinase travels from the plasma membrane to lysosomes via endocytosis, linking cell-surface signals to lysosome regulation.
- FGR inhibition or deletion boosts lysosome numbers in mammalian cells through TFEB/TFE3 activation.
- FGR acts by recruiting and activating AKT2 at the lysosomal surface, which phosphorylates and inactivates TFEB/TFE3.
- The pathway is evolutionarily conserved, identified first in C. elegans and confirmed in mammalian cells.
- Targeting FGR may offer a new strategy to enhance lysosomal clearance and counter cellular aging.
Methodology
Researchers developed a C. elegans heterologous TFE3 activation system to identify kinases regulating lysosome biogenesis, then validated findings in mammalian cell lines using genetic knockouts and pharmacological FGR inhibitors. The study combined live imaging of lysosomal markers, co-immunoprecipitation, and phosphorylation assays to map the FGR–AKT2–TFEB/TFE3 signaling axis.
Study Limitations
Findings are based on invertebrate (C. elegans) and mammalian cell culture models; in vivo validation in aged animals or humans is lacking. The study does not directly address whether FGR activity changes with age or how this pathway interacts with known longevity pathways such as mTORC1. This summary is based on the abstract only, as the full paper was not accessible.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: